Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal rhIL-12 for Peritoneal Carcinomatosis in Ovarian/Peritoneal Cancer
NCT00016289Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Jul 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant interleukin-12 in ovarian epithelial cancer and primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Primary endpoints: Rate of remission determined by laparoscopy or laparotomy up to 2 years, Toxicity graded using the NCI CTC version 3.0 up to 2 years and 1 more. Started Jul 2001; status: completed.
02
Drugs
recombinant interleukin-12
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00016289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016289.